Atlantic Technology Ventures Inc Sample Contracts

AutoNDA by SimpleDocs
WHEREAS:
Registration Rights Agreement • March 23rd, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • Illinois
ARTICLE 1 DEFINITIONS
Asset Purchase Agreement • November 19th, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • New York
ARTICLE 1 CORPORATE GOVERNANCE AND MANAGEMENT
Stockholders Agreement • August 22nd, 2000 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT
Asset Purchase Agreement • November 19th, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • New York
BY AND AMONG
Agreement and Plan of Reorganization • May 15th, 1997 • Atlantic Pharmaceuticals Inc • Pharmaceutical preparations • California
UNDERWRITING AGREEMENT between TG THERAPEUTICS, INC.
Underwriting Agreement • March 9th, 2017 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York

The undersigned, TG Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with Jefferies LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Warrant No. 2
Atlantic Technology Ventures Inc • March 31st, 2000 • Pharmaceutical preparations • Delaware
Exhibit 10.64 ASSET PURCHASE AGREEMENT
Asset Purchase Agreement • April 1st, 2002 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • Ohio
AMENDMENT TO PREFERRED STOCK PURCHASE AGREEMENT
Preferred Stock Purchase Agreement • November 20th, 2000 • Atlantic Technology Ventures Inc • Pharmaceutical preparations
RECITALS:
Securities Purchase Agreement • December 6th, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • New York
TG THERAPEUTICS, INC. 8,500,000 Shares of Common Stock Underwriting Agreement
Tg Therapeutics, Inc. • May 18th, 2020 • Pharmaceutical preparations • New York

TG Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,500,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,275,000 shares of common stock, par value $0.001 per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock, par value $0.001 per share, of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

FIRST AMENDMENT TO
Employment Agreement • April 14th, 2003 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations
TG THERAPEUTICS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
Tg Therapeutics, Inc. • March 20th, 2020 • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
TG THERAPEUTICS, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market Issuance Sales Agreement
Sales Agreement • December 31st, 2015 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
WITNESSETH:
Escrow Agreement • November 20th, 2000 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • North Carolina
ADDENDUM TO STOCK OPTION AGREEMENT
Stock Option Agreement • November 8th, 1996 • Atlantic Pharmaceuticals Inc • Pharmaceutical preparations
UNDERWRITING AGREEMENT
Underwriting Agreement • July 18th, 2013 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York

TG Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”) for whom Roth Capital Partners, LLC is acting as representative (the “Representative”) an aggregate of 5,700,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has granted the Underwriters the option to purchase an aggregate of up to 855,000 shares of Common Stock (the “Option Shares”) as may be necessary to cover over-allotments made in connection with the offering pursuant to Section 4(b) hereof. The Firm Shares and the Option Shares are collectively referred to as the “Shares.”

ADDENDUM TO STOCK OPTION AGREEMENT
Stock Option Agreement • November 8th, 1996 • Atlantic Pharmaceuticals Inc • Pharmaceutical preparations
RECITALS
Stock Repurchase Agreement • December 11th, 2000 • Atlantic Technology Ventures Inc • Pharmaceutical preparations
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT
Employment Agreement • May 15th, 2003 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
RECITALS
Repurchase Agreement • March 14th, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations
1.4 "B&L PATENTS" means all United States patent applications and their foreign
License Agreement • May 22nd, 1998 • Atlantic Pharmaceuticals Inc • Pharmaceutical preparations • California
FORM OF REGISTRATION RIGHTS AGREEMENT
Form of Registration Rights Agreement • June 29th, 2001 • Atlantic Technology Ventures Inc • Pharmaceutical preparations • Illinois
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!